Outcomes of Hydroxyurea Accessed via Various Means and Barriers Affecting Its Usage Among Children with Sickle Cell Anaemia in North-Western Tanzania
Emmanuela E Ambrose,Benson R Kidenya,Mwesige Charles,Joyce Ndunguru,Agnes Jonathan,Julie Makani,Irene K Minja,Paschal Ruggajo,Emmanuel Balandya
DOI: https://doi.org/10.2147/JBM.S380901
2023-01-21
Journal of Blood Medicine
Abstract:Emmanuela E Ambrose, 1 Benson R Kidenya, 2 Mwesige Charles, 3 Joyce Ndunguru, 4 Agnes Jonathan, 4 Julie Makani, 4 Irene K Minja, 4, 5 Paschal Ruggajo, 4, 6 Emmanuel Balandya 4, 7 1 Department of Paediatrics and Child Health, Catholic University of Health and Allied Sciences, Mwanza, Tanzania; 2 Department of Biochemistry and Molecular Biology, Catholic University of Health and Allied Sciences, Mwanza, Tanzania; 3 Department of Laboratory Services, Bugando Medical Centre, Mwanza, Tanzania; 4 Department of Haematology and Blood Transfusion, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania; 5 Department of Restorative Dentistry, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania; 6 Department of Internal Medicine, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania; 7 Department of Physiology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania Correspondence: Emmanuela E Ambrose, Department of Paediatrics and Child Health, Catholic University of Health and Allied Sciences, P.O. Box 1464, Mwanza, Tanzania, Tel +255789733833, Fax +255282500799, Email Purpose: To assess clinical and haematological outcomes of Hydroxyurea accessed via various access means and uncover the barriers to its utilization in children with Sickle cell anaemia (SCA), North-western Tanzania. Patients and Methods: A retrospective study was conducted between October 2020 and April 2021 at Bugando Medical Centre (BMC) through review of medical files to compare the clinical and haematological outcomes among children with SCA at baseline and followed up retrospectively for at least one year of hydroxyurea utilization, accessed via cash, insurance and projects. Subsequently, a cross-sectional survey was conducted among parents and caregivers to ascertain the barriers to access of hydroxyurea via the various means. The p-values < 0.05 were considered statistically significant. Results: We identified 87 children with SCA who were on hydroxyurea for at least one year. The median age at baseline (before hydroxyurea) was 99 [78– 151] months, and 52/87 (59.8%) were male. Compared to baseline, there was a significant reduction in proportion of patients reporting vaso-occlusive crisis, admissions and blood transfusions, a significant increase in Haemoglobin and mean corpuscular volume, conversely a significant reduction in absolute neutrophil and reticulocytes to both insurance and project participants. There was no significant change in most of these parameters among patients who accessed hydroxyurea via cash. Further, a total of 24/87 (27.6%) participants reported different barriers to access of hydroxyurea, where 10/24 (41.7%) reported hydroxyurea to be very expensive, 10/24 (41.7%) reported insurance challenges, and 4/21 (16.6%) reported unavailability of the drug. Conclusion: The paediatric patients utilizing hydroxyurea accessed via insurance and projects, but not cash, experienced significant improvement in the clinical and haematological outcomes. Several barriers for access to hydroxyurea were observed which appeared to impact these outcomes. These findings call for concerted efforts to improve the sustainable access to hydroxyurea among all patients with SCA. Keywords: sickle cell anaemia, hydroxyurea, access, outcomes, North-western Tanzania Sickle cell anaemia (SCA) is the most common genetic disorder of the red blood cells (RBCs) characterized by a single base mutation on the 6th codon of the β globin gene, resulting in substitution of amino acid valine for glutamic acid. 1 This change causes the RBCs to change to a sickle shape under hypoxic conditions due to polymerization of the haemoglobin molecules, 1,2 which is the cause for the multitude of complications in SCA such as cerebro-vascular accidents, vaso-occlusive crisis (VOC), acute chest syndrome, spleen sequestration and end organ damage. 2 Worldwide, Tanzania ranks fourth among countries with the highest annual births of individuals with SCA. 3 The high disease burden is mostly seen in regions along the Lake Victoria zone of the country. 3–6 Subsequently, an overwhelming number of patients with a myriad of SCA-related complications attend at the Bugando Medical Centre (BMC), the zonal tertiary referral hospital. 7 Hydroxyurea is the first disease modifying agent to be approved for use in SCA. 8 It does so by inducing foetal haemoglobin (HbF) production, decreasing intracellular sickle haemoglobin (HbS) polymerization within RBCs, decreasing -Abstract Truncated-